GTE to market Vidimedix offeringTelecommunications firm GTE and telemedicine software developer VidiMedix have formed a strategic alliance to market the VidiMedix Series 1000 PC-based telemedicine system. The system, which has received Food and
Telecommunications firm GTE and telemedicine software developer VidiMedix have formed a strategic alliance to market the VidiMedix Series 1000 PC-based telemedicine system. The system, which has received Food and Drug Administration 510(k) clearance, allows real-time remote patient/physician interaction and full-feature medical imaging, according to Austin, TX-based VidiMedix. VidiMedix 1000 consists of a group of desktop computer workstations that send, receive, and store a variety of medical information and images. Medical image and information can be simultaneously viewed, marked, and annotated with the system's whiteboarding and audio recording capabilities, according to the firm.
In other VidiMedix news, the company will participate in the Microsoft Certified Solution Provide program, which was formed by Microsoft to facilitate partnerships with information technology companies. VidiMedix is building upon Microsoft's forthcoming database technology to expand telemedicine beyond simple point-to-point connections, according to the firm. n
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.